Joel Sendek, Chief Financial Officer at Spero Therapeutics, Inc. (SPRO), sold 2,000 shares at $17.50 ($35K) on 2018-07-05, disclosed to the SEC on 2018-07-06.
Scheduled sale ($35k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.